Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism
about
PIG-A mutations in paroxysmal nocturnal hemoglobinuria and in normal hematopoiesisImplications of recent insights into the pathophysiology of paroxysmal nocturnal haemoglobinuria.Therapeutic implications of variable expression of CD52 on clonal cytotoxic T cells in CD8+ large granular lymphocyte leukemiaParoxysmal nocturnal hemoglobinuria (PNH): higher sensitivity and validity in diagnosis and serial monitoring by flow cytometric analysis of reticulocytes.Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individualsRecent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria.Silencing of genes required for glycosylphosphatidylinositol anchor biosynthesis in Burkitt lymphoma.Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab).Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells.Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).Biological and molecular characterization of PNH-like lymphocytes emerging after Campath-1H therapy.Early emergence of PNH-like T cells after allogeneic stem cell transplants utilising CAMPATH-1H for T cell depletion.Normal patterns of expression of glycosylphosphatidylinositol-anchored proteins on different subsets of peripheral blood cells: a frame of reference for the diagnosis of paroxysmal nocturnal hemoglobinuria.The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment.
P2860
Q28259136-31460F0D-AC7B-4CB0-A891-96A1CDCA3AB8Q33888594-5C50A020-6D75-46B0-B93B-5595BEAFCF87Q34612362-8BE20F3D-7684-4493-8736-38B37AB51239Q35093962-D73A554C-1A26-45E2-94FA-BFC5BED79A2AQ36340345-D4CE2281-4E49-41BB-B60C-B154AB55FDAFQ36780187-F82E16E7-3622-455D-A34C-4F87BF4F10B2Q37390398-31DCFEC3-4D26-482A-9BDC-D85946729A0EQ38065877-13991342-B74C-410F-AC06-6C9FA753206DQ40993369-19C51794-3366-4F4B-A02B-B4C3B6E59B28Q43430617-966A5EA1-25AA-4BBE-B182-84C64978C091Q43572271-9909F558-76B6-421A-B0CE-50F468B4225FQ47606524-0B301713-5D19-47AD-827F-3E338C587CFFQ50741743-5E137583-6421-41E8-B274-54CB4D55AE41Q52865040-B715D6BD-DD17-4F8B-BD99-6699A66572B2
P2860
Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Antibody selection against CD5 ...... mphocytes by a novel mechanism
@en
type
label
Antibody selection against CD5 ...... mphocytes by a novel mechanism
@en
prefLabel
Antibody selection against CD5 ...... mphocytes by a novel mechanism
@en
P2093
P2860
P356
P1433
P1476
Antibody selection against CD5 ...... mphocytes by a novel mechanism
@en
P2093
P2860
P304
P356
10.1042/BJ3220919
P407
P478
322 ( Pt 3)
P577
1997-03-01T00:00:00Z